
    
      This study is a multicenter, randomized, placebo-control, efficacy and safety study of
      VERU-111 for the treatment of COVID-19. Subjects will receive either 9mg of VERU-111 or
      matching placebo orally or through nasogastric tube daily for up to 21 days or until the
      subject is discharged from the hospital, whichever comes first. The primary efficacy endpoint
      of the study will be the proportion of subjects that die prior to Day 60.The total study
      duration for a subject from screening to follow up visit is planned to be62days. In addition
      to the safety of VERU-111, an evaluation of the efficacy of VERU-111 on SARS-CoV-2 (COVID-19)
      compared to the placebo control will be evaluated as part of the Independent Data Monitoring
      Committee (IDMC).
    
  